 |
|
|
| |
Detection of Baseline Resistance and HIV RNA Suppression to Week 48 in the SENSE Trial: Etravirine versus Efavirenz in Treatment Naïve Participants
|
| |
| |
Reported by Jules Levin
(ICAAC) InterScience Conference on Antimicrobial Agents and Chemotherapy,
Chicago, USA, September 2011
A.M. Geretti, MD PhD1,2, T. Conibear, PhD3, J. Johnson, PhD4, A. Hill2, PhD, S. Marks, MD5, L. Tambuyzer, MSc6, J. Vingerhoets, PhD6.
1University College London Medical School, London, United Kingdom; 2Liverpool University, Liverpool, United Kingdom; 3Royal Free Hampstead NHS Trust, London, United Kingdom; 4Centers for Disease Control and Prevention, Atlanta, GA; 5Janssen, Amsterdam, Netherlands; 6Tibotec-Virco, Beerse, Belgium.
----------------------------------------
The SENSE trial: Final 48-week analysis of etravirine (ETR) versus ...
www.natap.org/2011/IAS/IAS_60.htm
The SENSE trial: Final 48-week analysis of etravirine (ETR) versus efavirenz (EFV) in treatment-naïve patients. Reported by Jules Levin 6th IAS Conference on
Phase 2 double-blind, randomised trial of etravirine versus efavirenz ...
www.natap.org/2011/HIV/090511_01.htm
Aug 30, 2011 - Download the PDF here AiDS: Ahead of ... Abstract Background: The SENSE Trial compared etravirinewithefavirenzin treatment-naive patients
-----------------------------------------
|
| |
|
|
|
|
|
